BioCardia, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing continued operating losses and a reduced cash position compared to December 31, 2025.

Key Highlights

  • Net loss of $1.817 million for the three months ended September 30, 2026, compared to a net loss of $1.483 million in the same period of 2025, according to the filing.
  • Nine-month net loss of $5.689 million for the period ended September 30, 2026, versus $6.244 million for the nine months ended September 30, 2025.
  • Cash and cash equivalents of $2.224 million as of September 30, 2026, down from $2.496 million at December 31, 2025.
  • Total assets of $3.071 million and total stockholders' equity of $835 thousand as of September 30, 2026.
  • Shares outstanding increased to 15,138,782 as of November 11, 2026, from 10,755,647 at December 31, 2025, reflecting stock activity during the period.
  • Accumulated deficit reached $174.038 million as of September 30, 2026, up from $168.349 million at December 31, 2025.

BioCardia's Financial Position and Operating Results for the September 2026 Quarter

According to the filing, BioCardia, Inc. (NASDAQ:BCDA) reported a net loss of $1.817 million for the three months ended September 30, 2026, compared to a net loss of $1.483 million for the same quarter in 2025. Total costs and expenses for the third quarter of 2026 were $1.835 million, comprised of $1.235 million in research and development expenses and $600 thousand in selling, general and administrative expenses. The company reported total other income, net, of $18 thousand for the quarter, partially offsetting the operating loss.

For the nine months ended September 30, 2026, the registrant reported a net loss of $5.689 million, compared to $6.244 million for the nine months ended September 30, 2025. Research and development expenses for the nine-month period were $3.363 million, while selling, general and administrative expenses were $2.361 million. Net loss per share, basic and diluted, was $0.12 for the three months ended September 30, 2026, and $0.45 for the nine months ended September 30, 2026, based on weighted-average shares of 15,135,424 and 12,696,206, respectively.

The condensed consolidated balance sheet as of September 30, 2026 showed total assets of $3.071 million and total liabilities of $2.236 million, resulting in total stockholders' equity of $835 thousand. Cash and cash equivalents stood at $2.224 million, down from $2.496 million at December 31, 2025. The accumulated deficit increased to $174.038 million from $168.349 million over the same period. Common shares issued and outstanding grew to 15,138,782 from 10,755,647 at December 31, 2025. The company is classified as a non-accelerated filer and a smaller reporting company, as indicated on the cover page of the filing.

What Was Disclosed

BioCardia disclosed its unaudited condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, showing a third-quarter net loss of $1.817 million, cash of $2.224 million, and an accumulated deficit of $174.038 million as of that date.